I want to get continuous structured data on new clinical trial protocols, regulatory submission requirements, and outcome measures from global research registers, regulatory body websites, and academic publications.
Access real-time insights on clinical trials and regulations — streamlined automation replaces tedious manual searches
A saved example of what you can collect and monitor with Jsonify. Create your own version in Jsonify.
Build this in JsonifyYour original goal is prefilled.
Goal
I want to get continuous structured data on new clinical trial protocols, regulatory submission requirements, and outcome measures from global research registers, regulatory body websites, and academic publications.
Source coverage
- clinicaltrials.gov
- gov.uk
- ema.europa.eu
- who.int
- alltrials.net
- researchgate.net
- academic.oup.com
- thelancet.com
- sciencedirect.com
- biomedcentral.com
- clinicaltrialsregister.eu
- nctu.hsc.wvu.edu
Sample data
Illustrative sample data from the original configuration, not live or verified results.
| id | Source | TrialID | Title | Phase | Intervention | PrimaryOutcome | StartDate | LastUpdated | Status | Location | SampleSize |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | clinicaltrials.gov | NCT05812345 | Randomized Phase 2 Trial of ABX-201 vs Placebo in Treatment-Naïve Moderate COVID-25 | Phase 2 | ABX-201 oral 200 mg daily | Change in WHO Clinical Progression Scale at Day 14 | 2026-01-15 | 2026-02-02 | Recruiting | United States, Canada | 240 |
| 2 | ema.europa.eu | EUCTR2026-000123-45 | Open-label Phase 3 Study of OncoVax-P in HER2-negative Metastatic Breast Cancer | Phase 3 | OncoVax-P IV every 3 weeks + standard chemo | Progression-free survival at 12 months | 2025-12-01 | 2026-02-03 | Active, not recruiting | Germany, France, Spain | 640 |
| 3 | who.int | WHO-ITH-2026-001 | Cluster RCT of Community-based Malaria Prophylaxis in Rural Uganda | Phase 4 | Monthly DP (dihydroartemisinin–piperaquine) sachets | Incidence of symptomatic malaria episodes per 1000 person-years | 2025-11-20 | 2026-02-01 | Ongoing | Uganda | 4800 |
| 4 | clinicaltrialsregister.eu | CTR2026-78901 | Phase 1/2 Study of Lenti-CRISPR Therapy for Sickle Cell Disease | Phase 1/2 | Ex vivo Lenti-CRISPR autologous infusion | Percentage of patients with hemoglobin >9 g/dL at 6 months | 2025-12-10 | 2026-02-04 | Recruiting | United Kingdom, Netherlands | 48 |
| 5 | gov.uk | MHRA-CT-2026-012 | Randomized Controlled Trial of RSV Vaccine NVX-RSV in Adults ≥60 | Phase 3 | NVX-RSV single IM dose vs placebo | Vaccine efficacy against laboratory-confirmed RSV LRTI at 6 months | 2025-12-18 | 2026-02-03 | Recruiting | United Kingdom | 12000 |
| 6 | alltrials.net | AT-TRIAL-2026-77 | Comparative Effectiveness of Telemedicine Behavioral Therapy for Opioid Use Disorder | Phase 3 | Weekly telemedicine CBT vs in-person CBT | Retention in treatment at 24 weeks | 2025-12-05 | 2026-02-02 | Active, not recruiting | United States | 900 |
| 7 | researchgate.net | RG-2026-PRO-09 | Pilot Trial of Novel Inhaled Insulin Formulation in Type 1 Diabetes | Phase 1 | Inhaled insulin micro‑aerosol, dose-escalation | Safety: rate of hypoglycemia episodes within 28 days | 2026-01-20 | 2026-02-04 | Recruiting | Australia | 36 |
| 8 | thelancet.com | TLC-CLIN-2026-02 | Multicentre Trial of High-dose IV Vitamin C in Severe Sepsis | Phase 3 | IV Vitamin C 6 g q6h for 4 days + standard care | 28-day all-cause mortality | 2025-11-30 | 2026-02-01 | Ongoing | Multi-country (UK, India, Brazil) | 1500 |
| 9 | academic.oup.com | OUP-TR-2026-11 | Randomized Study of Omega-3 Supplementation for Prevention of Postoperative Atrial Fibrillation | Phase 4 | Omega-3 2 g daily vs placebo for 30 days | Incidence of AF within 30 days post-cardiac surgery | 2025-12-22 | 2026-02-03 | Recruiting | United States | 1200 |
| 10 | sciencedirect.com | SD-RES-2026-334 | Phase 2 Trial of Oral TYK2 Inhibitor for Moderate-to-Severe Psoriasis | Phase 2 | TYK2 inhibitor 10 mg daily | Percent achieving PASI75 at Week 12 | 2026-01-10 | 2026-02-02 | Recruiting | Brazil, Mexico | 240 |
| 11 | biomedcentral.com | BMC-CLIN-2026-05 | Double-blind Trial of Probiotic Regimen to Prevent Antibiotic-associated Diarrhea in Elderly | Phase 4 | Multi-strain probiotic BID during antibiotics | Incidence of AAD within 30 days | 2025-12-28 | 2026-02-04 | Recruiting | United Kingdom | 800 |
| 12 | clinicaltrials.gov | NCT05900111 | Adaptive Platform Trial of Broad-spectrum Antivirals for Emerging Respiratory Viruses | Phase 2/3 | Arm A: Broad-spectrum antiviral X; Arm B: Standard care | Time to sustained clinical recovery (7-day symptom-free) | 2026-01-25 | 2026-02-03 | Recruiting | Global (US, UK, India, South Africa) | 2400 |
| 13 | nctu.hsc.wvu.edu | WVU-NCTU-2026-09 | Feasibility Study of Wearable ECG Monitoring to Detect Postoperative AF | Phase 2 | Wearable continuous ECG patch vs standard telemetry | Detection rate of AF within 7 days post-op | 2026-01-12 | 2026-02-01 | Ongoing | United States | 300 |
| 14 | clinicaltrialsregister.eu | CTR2026-99800 | Phase 2b Study of Oral GLP-1 Receptor Agonist in Nonalcoholic Steatohepatitis (NASH) | Phase 2b | GLP-1 RA 5 mg SC weekly vs placebo | Change in liver fat fraction by MRI at 24 weeks | 2025-12-15 | 2026-02-04 | Recruiting | Italy, Spain | 420 |
| 15 | gov.uk | MHRA-CT-2026-033 | Randomized Trial of Short-course Antibiotics for Uncomplicated UTIs in Women | Phase 3 | 3-day vs 7-day antibiotic regimen (nitrofurantoin) | Clinical cure at Day 14 | 2026-01-05 | 2026-02-02 | Recruiting | United Kingdom | 1500 |
| 16 | who.int | WHO-VAX-2026-012 | Phase 2 Study of Novel Dengue Vaccine Candidate in Adolescents | Phase 2 | Dengue tetravalent recombinant vaccine, 2 doses IM | Neutralizing antibody GMT at Day 56 | 2025-12-02 | 2026-02-03 | Active, not recruiting | Indonesia, Philippines | 900 |
| 17 | thelan cet.com | TLC-ONC-2026-08 | Neoadjuvant Immunotherapy with Anti-PD-1 + Chemo in Triple-negative Breast Cancer | Phase 2 | Anti-PD-1 IV q3w x4 + standard chemo | Pathologic complete response rate at surgery | 2025-12-07 | 2026-02-01 | Recruiting | United States, Canada, UK | 180 |
| 18 | researchgate.net | RG-2026-ENDO-21 | Randomized Trial of Low-dose Estradiol Vaginal Ring for Genitourinary Syndrome of Menopause | Phase 3 | Estradiol ring 12-week vs placebo | Change in GSM symptom score at 12 weeks | 2026-01-18 | 2026-02-04 | Recruiting | Germany, Sweden | 480 |
| 19 | academic.oup.com | OUP-DERM-2026-03 | Topical Small-molecule JAK Inhibitor Cream for Atopic Dermatitis | Phase 2 | JAK inhibitor 2% cream BID vs vehicle | EASI score reduction at Week 8 | 2026-01-08 | 2026-02-02 | Recruiting | United States, Canada | 300 |
| 20 | sciencedirect.com | SD-NEURO-2026-17 | Phase 3 Trial of Subcutaneous Anti-Tau Antibody in Early Alzheimer's Disease | Phase 3 | Anti-Tau mAb 600 mg SC q4w | Change in CDR-SB at 18 months | 2025-11-25 | 2026-02-03 | Active, not recruiting | United States, Japan, South Korea | 2600 |
| 21 | biomedcentral.com | BMC-PSY-2026-02 | Digital CBT App vs Waitlist for Adolescent Anxiety: Pragmatic Trial | Phase 3 | Digital CBT app access for 12 weeks | Change in GAD-7 score at 12 weeks | 2026-01-22 | 2026-02-04 | Recruiting | United Kingdom | 1200 |
| 22 | clinicaltrials.gov | NCT05890077 | Dose-ranging Phase 1 Study of Novel Anticoagulant FXIa Inhibitor | Phase 1 | FXIa inhibitor oral tablets, single ascending doses | Dose-limiting adverse events within 28 days | 2026-01-30 | 2026-02-04 | Recruiting | United States | 72 |
| 23 | clinicaltrialsregister.eu | CTR2026-45012 | Randomized Study of Early Mobilization Protocol After Hip Fracture Repair | Phase 4 | Enhanced mobilization protocol vs standard physiotherapy | Time to independent ambulation within 30 days | 2025-12-20 | 2026-02-02 | Ongoing | Sweden, Norway | 560 |
| 24 | gov.uk | MHRA-CT-2026-078 | Vaccine Immunogenicity Study of Seasonal Influenza Formulation in Healthcare Workers | Phase 4 | Quadrivalent influenza vaccine annual dose | Seroconversion rate at Day 28 | 2026-01-10 | 2026-02-01 | Recruiting | United Kingdom | 2000 |
| 25 | who.int | WHO-PRT-2026-005 | Water, Sanitation and Hygiene (WASH) Intervention Trial to Reduce Childhood Diarrhea | Phase 4 | Community WASH package vs standard practice | Incidence rate of diarrheal episodes in children <5 over 12 months | 2025-12-05 | 2026-02-03 | Ongoing | Bangladesh | 7200 |
| 26 | alltrials.net | AT-ONC-2026-19 | Registry-linked Trial of CAR-T Toxicity Mitigation Strategies | Phase 2 | Early IL-6 blockade protocol vs standard supportive care | Incidence of Grade ≥3 cytokine release syndrome within 30 days | 2026-01-14 | 2026-02-04 | Recruiting | United States | 360 |
| 27 | researchgate.net | RG-IMMU-2026-14 | First-in-Human Study of Intranasal Monoclonal Antibody for Seasonal Allergy | Phase 1 | Intranasal mAb spray, single dose cohort | Local tolerability and symptom scores at 7 days | 2026-01-05 | 2026-02-02 | Recruiting | Canada | 48 |
| 28 | thelancet.com | TLC-INF-2026-06 | Cluster Randomized Trial of Antibiotic Stewardship in Neonatal Units | Phase 3 | Stewardship bundle vs usual care | Antibiotic days per 1000 patient-days over 6 months | 2025-11-28 | 2026-02-01 | Ongoing | South Africa, Kenya | 4200 |
| 29 | academic.oup.com | OUP-CARD-2026-07 | Randomized Trial of Remote Ischemic Conditioning to Reduce Myocardial Injury | Phase 2 | RIPC device perioperative vs sham | Troponin rise >5x baseline within 48 hours | 2026-01-02 | 2026-02-03 | Recruiting | United Kingdom | 540 |
| 30 | sciencedirect.com | SD-ENDO-2026-29 | Phase 2 Trial of Oral SGLT3 Inhibitor in Diabetic Kidney Disease | Phase 2 | SGLT3 inhibitor 10 mg daily | Change in eGFR slope at 52 weeks | 2025-12-12 | 2026-02-04 | Active, not recruiting | United States, Canada, Australia | 600 |
Insights and analytics
- Total New Clinical Trial Protocols (metric)
- Total Regulatory Submissions (metric)
- Total Outcome Measures Identified (metric)
- Trends in New Clinical Trials Over Time (line)
- Top Countries by Clinical Trials Registered (bar)
- Distribution of Clinical Trials by Phase (pie)
- Regulatory Submissions by Type (donut)
- Most Common Outcome Measures (horizontal_bar)
- Latest Clinical Trials Updates (table)
- Recent Regulatory Changes (table)
- Key Observations on Clinical Trial Trends (insights)
- Cumulative Outcomes Measures Over Time (area)
Change notifications
- New Trial Detected — New protocol available clinicaltrials.gov
- Regulatory Update — New requirements published ema.europa.eu
- Outcome Measure Updated — New primary outcome defined clinicaltrialsregister.eu
- Protocol Removed — Trial protocol no longer available clinicaltrials.gov
- Sample Size Adjusted — Sample size increased to 500 who.int
Integrations and delivery
- api
- bigquery
Make this your own
Start with this goal in Jsonify, then choose the sources and data you need.
Build this in Jsonify